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Abstract
In this study, the potential influence of resveratrol (3,5,4′-trihydroxy-trans-stilbene) in signal transducer and activator
of transcription 3 (STAT3) signaling of medulloblastoma cells was evaluated by checking the status of STAT3 sig-
naling and its downstream gene expression in two medulloblastoma cell lines (UW228-2 and UW228-3) with and
without resveratrol treatment. The results revealed that resveratrol induced neuronal differentiation of medulloblas-
toma cells. Signal transducer and activator of transcription 3 expression and phosphorylation were detected in
normally cultured UW228-2 and UW228-3 cells that were apparently attenuated after resveratrol treatment. The
expression of STAT3 downstream genes, survivin, cyclin D1, Cox-2, and c-Myc, was suppressed but Bcl-2 was
enhanced by resveratrol. Meanwhile, the production and secretion of leukemia inhibitory factor, a STAT3 activator,
became active in resveratrol-treated cells. To further ascertain the significance of STAT3 signaling for medulloblas-
toma cells, AG490, a selective inhibitor of STAT3 phosphorylation, was used to treat UW228-3 cells. Phosphory-
lation of STAT3 was inhibited by AG490 accompanied with growth suppression, differentiation-like changes, and
down-regulation of survivin, cyclin D1, Cox-2, and c-Myc. Our data thus suggest the importance of STAT3 signaling
in maintenance and survival of medulloblastoma cells. This signaling may be the major target of resveratrol. En-
hanced leukemia inhibitory factor and Bcl-2 expressions in resveratrol-treated cells might reflect a compensatory
response to the loss of STAT3 function.
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Introduction
Medulloblastoma is the commonest malignant brain tumor in child-
hood. Despite the improved combination of surgery, radiotherapy, and
chemotherapy, the outcome of medulloblastomas, especially those de-
veloped in early ages, remains poor due to the difficulty in removing
the highly invasive intracranial tumor radically and the short- and
long-term adverse effects of conventional postsurgical adjuvant thera-
pies [1–3]. Consequently, exploration of reliable and less toxic chemo-
therapeutic approach is urgently required for better management of
this sort of malignancy.
Resveratrol (3, 5, 4′-trihydroxy-trans-stilbene) is a plant polyphenol
that is naturally occurring in grapes, red wine, and peanuts and has
chemopreventive and anticancer properties [4,5]. This harmless com-
pound exhibits anticancer activities in multiple human cancers with
less-defined molecular mechanisms [4]. We found that resveratrol
could induce differentiation and apoptosis of medulloblastoma cells
through Fas-independent pathway [6], suggesting the involvement
of other molecular factor(s) in the course of resveratrol action. c-Myc
is a key element in controlling cell growth, differentiation, and survival
[7], which is amplified and/or overexpressed in a great proportion of
medulloblastomas [8]. Our previous study demonstrated that c-Myc
down-regulation was closely associated with the antimedulloblastoma
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effect of resveratrol [9]. Because c-Myc expression can be regulated by
several signaling pathways including the one mediated by Janus kinase
(JAK)/STAT3, resveratrol-induced c-Myc down-regulation implicates
potential disorder(s) of certain signal pathways in the treated cells.
Signal transducer and activator of transcription 3 (STAT3) is a kind
of transcription factor that is phosphorylated by JAK kinases in re-
sponse to cytokine activation of a cell surface receptor tyrosine kinases
[10]. Signal transducer and activator of transcription 3–mediated cell
growth, differentiation, and survival depend on the ligand–receptor
binding of IL-6 family members such as IL-6 and leukemia inhibi-
tory factor (LIF) [11]. On activation, STAT3 molecules are transloca-
lized to nucleus where they activate transcription of a series of target
genes including c-Myc, survivin, Cox-2, and cyclin D1 that are closely
associated with the growth, survival, and progression of cancer cells
[8,12–14]. The activation of STAT3 has been described in human
medulloblastomas [15]. Inhibition of STAT3 signaling may commit
medulloblastoma cells to growth arrest and apoptosis [16]. Negative
regulation of STAT3 activation by resveratrol has been found in
multiple myeloma cells [17] and prostate cancer cells [18] but re-
mains unknown in medulloblastomas. Because LIF is constitutively
expressed as an autocrinal growth factor in medulloblastoma cells
in vivo and in vitro [19] and expressions of c-Myc and other STAT3
target genes are commonly observed in medulloblastoma cells [8,13],
it would be possible that resveratrol conducts its antimedulloblas-
toma effects through altering STAT3 activation and/or production.
This issue was addressed in the current study through multiple exper-
imental approaches.
Materials and Methods
Cell Culture and Treatments
Established human medulloblastoma cell lines, UW228-2 and
UW228-3, were derived from the surgical specimen of a 9-year-old
female patient and were established by independent cultures of two
cell aliquots from the tumor [20]. Both of them were cultured in
Eagle’s minimal essential medium containing 10% fetal bovine serum
(FBS; Gibco Life Science, Grand Island, NY) under 37°C and 5%
CO2 condition. The cells (5 × 10
4/ml) were plated to ϕ60- and
ϕ100-mm dishes (Nunc A/S, Roskilde, Denmark) and incubated
for 24 hours before further experiments. For morphologic evaluation
and immunocytochemical (ICC) and immunofluorescent (IF) stain-
ing, the coverslips were put into the dishes before initial cell seeding
and collected regularly during the experiments.
Resveratrol (Sigma Chemical, Inc, St. Louis, MO) was dissolved in
dimethylsulfoxide (Sigma) to a stock concentration of 100 mM and
diluted with culture medium to an optimal working concentration
of 100 μM just before use [6]. The cells treated by the same concen-
tration of DMSO were used as background control. The drug treat-
ment lasted for 48 or 72 hours depending on the experimental
purposes. The cells were checked in 12-hour intervals, followed by cell
collection for protein and RNA extractions and in situ examination.
Total cell numbers and cell viability of the cells without and with
100-μM resveratrol treatment were determined at 0-, 24-, and 48-hour
time points by staining the single-cell suspensions with 0.25% trypan
blue and counting the stained and unstained cells with the hemo-
cytometers. Cell-bearing coverslips were harvested at each checking
point and fixed properly for morphologic, ICC, and IF examinations.
Each of experimental groups was set in triplicate, and the experiments
were repeated at least three times to establish confidential conclusions.
Flow Cytometry Evaluation
To determine the effects of resveratrol on cell cycle, UW228-2 and
UW228-3 cells were plated at a density of 5 × 104/ml on 60-mm-
diameter dishes. The cells treated by 100-μM resveratrol were col-
lected in 12-hour intervals. For staining with DNA dye, the cells were
resuspended in 0.5 to 1 ml of propidium iodide solution containing
RNase and were incubated at 37°C for 30 minutes. Cell cycle profiles
were obtained with a FACSvantage flow cytometer (Becton Dickinson,
San Jose, CA), and data were analyzed with ModFit software (Verity
Software House, Inc, Topsham, ME).
Immunocytochemical and Immunofluorescent Staining
Immunocytochemical staining was performed on the coverslips ob-
tained from each of the experimental groups. The antibodies against
STAT3, phosphorylated-STAT3 (p-STAT3), survivin, c-Myc, cyclin D1,
Cox-2, LIF, glial fibrillary acidic protein (GFAP), and synaptophysin
were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz,
CA) and used according to the manufacturer’s instruction. Briefly,
the coverslips were washed with phosphate-buffered solution (PBS,
pH 7.4), incubated for 10 minutes in 3% H2O2 and then with the ap-
propriately diluted first antibody at 37°C for 60 minutes in a humid
chamber, followed by the treatments with reagent A containing polymer
enhancer for 20 minutes and with reagent B containing polymerized
horseradish peroxidase (HRP) anti–mouse/rabbit IgG for 30 minutes
(Zymed Lab, Inc, San Francisco, CA). Color reaction was developed
using 3,3′-diaminobenzidine tetrahydrochloride.
For IF staining, the coverslips were rinsed with PBS (pH 7.4),
fixed for 20 minutes in 80% cold acetone and stored at −20°C until
use. After being blocked with 10% goat serum in PBS for 20 min-
utes, the coverslips were incubated overnight with primary antibodies
against target proteins in humid chamber at 4°C, followed by coincu-
bation with fluorescence-labeled goat antirabbit or rabbit antimouse
IgG (1:100; Santa Cruz Biotechnology, Inc) in a 37°C humid chamber
for 60 minutes in darkness. The coverslips were sealed with 90% glyc-
erol, observed, and photographed (DP70 Digital Camera; Olympus,
Tokyo, Japan) under a fluorescence microscope (BX51; Olympus).
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
Total cellular RNA were isolated from each of experimental groups
using Trizol solution (Life Technologies, Grand Island, NY). Reverse
transcription (RT) was performed on RNA samples, followed by po-
lymerase chain reaction (PCR) amplification. For RT, 0.5 μg of the
RNA sample was added to 20 μl of RTreaction mixture (Takara, Inc,
Ltd, Dalian, China) containing 4 μl of MgCl2, 2 μl of 10 × RNA
PCR buffer, 9.5 μl of RNase-free distilled H2O, 2 μl of deoxyribo-
nucleotide triphosphate mixture, 0.5 μl of RNase inhibitor, 1 μl of
AMV reverse transcriptase, and 1 μl of oligo dT-adaptor primer. The
reaction was carried out by treating the samples at 55°C for 30 min-
utes, at 99°C for 5 minutes, and at 5°C for 5 minutes. Polymerase
chain reaction was conducted using the primers specific for each of
the target genes (Table 1). Briefly, 2.5 μl of RT products were mixed
with 16 μl of PCR-grade water, then with 6.5 μl of PCR working
solution containing 1 × PCR buffer, 1 μl of deoxyribonucleotide tri-
phosphate, 2.5 units of Taq DNA polymerase, and 50 pM upstream
and downstream primers for human STAT3, survivin, Cox-2, cyclin
D1, c-Myc, Bcl-2, LIF, GFAP, and synaptophysin, respectively. Poly-
merase chain reactions for individual genes were performed according
to the conditions reported elsewhere [21–29]. The PCR products
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were resolved on 1% agarose gel containing ethidium bromide (0.5 μg/
ml). The bands were visualized and photographed using UVP Bio-
spectrum Imaging System (UVP, Inc, Upland, CA). The PCR prod-
ucts generated from the same RT solution by a pair of β-actin primers
were cited as internal quantitative controls.
Protein Preparation and Western Blot Analyses
Total cellular proteins were prepared from the cells under differ-
ent culture conditions by the method described previously [9]. For
Western blot analyses, the sample proteins (50 μg/well) were separated
by electrophoresis in 10% sodium dodecylsulfate–polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride
membrane (Amersham, Buckinghamshire, UK). The membrane was
blocked with 5% skimmed milk in TBS-T (10 mM Tris–Cl, pH 8.0,
150 mM NaCl, and 0.5% Tween 20) at 4°C overnight, rinsed three
times (10 minutes each time) with TBS-T, followed by 3 hours of in-
cubation at room temperature with the first antibodies in appropriate
concentrations followed by 1 hour of incubation with HRP-conjugated
antimouse or -rabbit IgG (Zymed Lab, Inc). The bound antibody was
detected using the enhanced chemiluminescence system (Roche
GmbH, Mannheim, Germany). After removing the labeling signal
by incubation with stripping buffer (62.5 mM Tris–HCl, pH 6.7,
100 mM 2-mercaptoethanol, 2% SDS) at 55°C for 30 minutes, the
membrane was reprobed with other antibodies one by one by the same
experimental procedures until all of the parameters were examined.
Condition Medium Collection and LIF-Oriented
Western Blot Analysis
Cells cultured under normal condition and treated by 100-μM res-
veratrol for 36 hours were harvested for total protein preparation.
Meanwhile, the cell-free culture media were collected from the ex-
perimental and normal culture groups, respectively. The medium con-
taining 10% FBS was used as background control. The sample media
were concentrated by centrifugal filtration through YM-10 filters
(Millipore, Bedford, MA) and were adjusted to a working protein
concentration of 50 μg/μl. A total of 3 μl of working solutions were
prepared from each of the three samples; half of them were used
for Western blot analysis to check secreted LIF by the method de-
scribed previously. As quantitative control, the remaining half of the
sample proteins were electrophoresed in an SDS-PAGE gel, stained
by Coomassie brilliant blue (Bio-Rad Laboratory, Richmond, CA)
and photographed under a UV transilluminator (Bio-spectrum Imag-
ing System; UVP, Inc).
Leukemia Inhibitory Factor Immunoelectron
Microscopic Examination
Coverslips with UW228-3 cells were fixed for 30 minutes with
2% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) contain-
ing 2.5% glutaraldehyde. They were washed with PBS (pH 7.4), in-
cubated for 10 minutes in 3% H2O2 and then with an antihuman
LIF antibody in a dilution rate of 1:80 at 37°C for 60 minutes, fol-
lowed by the treatments with reagent A containing polymer enhancer
for 20 minutes and with reagent B containing polymerized HRP
antirabbit IgG for 30 minutes (Zymed Lab, Inc). Color reaction
was developed using 3,3′-diaminobenzidine tetrahydrochloride. After
washing with PBS for three times (10 minutes each time), the cover-
slips were fixed in 2.5% glutaraldehyde (30 minutes, 50 mM caco-
dylate buffer, pH 7.2) and 2% OsO4 (30 minutes, the same buffer).
Ultrathin sections (0.1 μm) were prepared and examined under a
Philips CM100 transmission electron microscope (FEI Company,
Hillsboro, OR). Images were captured by charge-coupled device cam-
era equipped with TCL-EM-Menu version 3 (Tietz Video and Image
Processing Systems GmbH, Gaunting, Germany) as described else-
where [30]. The samples without primary antibody incubation were
used as negative controls.
Inhibition of STAT3 Activation with AG490
AG490 is a JAK2-specific inhibitor and therefore selectively inhibits
STAT3 phosphorylation. This reagent (Sigma) was dissolved in
DMSO to a stock concentration of 50 mM and was diluted to the
final concentration of 60 μM with conventional culture medium just
before use [31]. Three experimental groups were set as follows: group
1, normal culture; group 2, treatment with 1.2‰ DMSO as back-
ground control; group 3, treatment with 60 μMAG490. For morpho-
logic evaluation and ICC staining for p-STAT3, cyclin D1, survivin,
Bcl-2, Cox-2, c-Myc, LIF, and synaptophysin, the coverslips were put
into the dishes before initial cell seeding and were collected after a
72-hour treatment during the experiments.
Results
Resveratrol-Induced Neuron-Oriented Differentiation
Under normal culture condition, UW228-2 and -3 cells were ellip-
tical. They exhibited elongated phenotype after 100-μM resveratrol
treatment for 24 hours and showed apoptosis at the 48-hour time
point. Flow cytometry analyses (Figure 1A) revealed that the fractions
of UW228-3 cells in G1 and S phases were 41.7% and 58.3% in nor-
mally cultured cells, and turned to 82.9% and 17.1% on 100-μM res-
veratrol treatment for 24 hours and to 93.3% and 6.2% for 48 hours;
similar phenomenawere found in resveratrol-treatedUW228-2 cells. Ex-
amination of neural differentiation biomarkers showed that both GFAP
and synaptophysin were negative in normally cultured UW228-2
and UW228-3 cells. On resveratrol treatment, synaptophysin but not
GFAP became expressed in both cell lines (Figure 2B).
The chemosensitivities of UW228-2 and -3 cell lines to resveratrol
were evaluated by measuring total cell numbers and cell viability in
Table 1. Sequences of RT-PCR Primers.
Parameters Primer Sequences Annealing
Temperature (°C)
Product
Size (bp)
Reference
STAT3 F: 5′-gggtggagaaggacatcagcggtaa-3′ 58 298 [21]
R: 5′-gccgacaatactttccgaatgc-3′
survivin F: 5′-ggcatgggtgccccgacgttg-3′ 58 439 [22]
R: 5′-cagaggcctcaatccatggca-3′
Bcl-2 F: 5′-tgtggccttctttgagttcg-3′ 56 280 [23]
R: 5′-tcacttgtggctcagatagg-3′
LIF F: 5′-ctgttggttctgcactgga-3′ 56 350 [24]
R: 5′-gggttgaggatcttctggt-3′
c-Myc F: 5′-tggtcttcccctaccctctcaac-3′ 56 265 [25]
R: 5′-gatccagactctgaccttttgcc-3′
GFAP F: 5′-tgagtcgctggaggaggagat-3′ 58 285 [26]
R: 5′-tagtcgttggcttcgtgctt-3′
synaptophysin F: 5′-ccgccagacagggaacacat-3′ 61 621 [27]
R: 5′-agggggcccactcaagactg-3′
Cox-2 F: 5′-ttcaaatgagattgtgggaaaattgct-3′ 50 305 [28]
R: 5′-agatcatctctgcctgagtatctt-3′
cyclin D1 F: 5′-ctgtgctgcgaagtggaaaccat-3′ 57 257 [29]
R: 5′-ttcatggccagcgggaagacctc-3′
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12-hour intervals during the treatment by staining the suspended
single cells with 0.25% trypan blue and counting the stained and
unstained cells with the hemocytometers. The results revealed that
after resveratrol treatment for 0, 12, 24, 36, and 48 hours, the per-
centage of dead cells was 0%, 10%, 31.03%, 33.33%, and 42.86%
in the UW228-3 population and 0%, 2.7%, 18.6%, 16.6% and
22.7% in UW228-2 cells, respectively (Figure 1B), indicating that
UW228-3 cells were more sensitive to resveratrol.
Resveratrol Inhibited STAT3 Transcription and Activation
To elucidate the effects of resveratrol on STAT3 signaling, RT-PCR
for STAT3 was performed on the RNA samples extracted from the
cells without and with resveratrol treatment. As shown in Figure 3,
STAT3 was expressed in normally cultured UW228-2 and -3 cells,
which was down-regulated in both cell lines after resveratrol treatment.
Immunofluorescent and ICC staining were performed on the same
experimental groups to further check the location and relative abun-
dance of STAT3 and p-STAT3 in UW228-2 and -3 cells. The result
of IF staining showed that STAT3 (red fluorescence–labeled protein)
was distributed in cytoplasm and nuclei of UW228-2 and -3 cells
under the normal culture condition, which became apparently re-
duced in the nuclei after resveratrol treatment (Figure 2A). Immuno-
cytochemical staining for p-STAT3 showed positive staining mainly
in the nuclei of UW228-2 and -3 cells. After resveratrol treatment,
p-STAT3 immunolabeling was diminished in the nuclei of the two
cell lines (Figure 2A). In accordance with the RT-PCR, ICC, and IF
results, Western blot analysis with the antibody against p-STAT3
showed distinct p-STAT3 reduction in resveratrol-treated UW228-2
and -3 cells (Figure 2C ).
Resveratrol Altered STAT3 Downstream Gene Expressions
To elucidate the effects of resveratrol on STAT3 downstream genes,
the expressions of c-Myc, survivin, Cox-2, cyclin D1, and Bcl-2 were
examined by the methods of RT-PCR, ICC and IF staining, andWest-
ern blot analysis. As described previously [9], c-Myc was expressed
in normally cultured UW228-2 and -3 cells and down-regulated in
resveratrol-treatedUW228-2 and, especially, UW228-3 cells (Figure 3).
The same tendency of survivin, Cox-2, and cyclin D1 expression was
evidenced in the two cell lines (Figure 2). However, Bcl-2 transcription
and production was enhanced by resveratrol in both UW228-2 and
-3 cells (Figure 2, A–C ).
Resveratrol Promoted LIF Expression and Secretion
Leukemia inhibitory factor is constitutively expressed in medullo-
blastoma cells in vivo and in vitro as autocrinal growth factor [19].
RT-PCR and Western blot analyses demonstrated that LIF was ob-
viously up-regulated in resveratrol-treated UW228-2 and -3 cells (Fig-
ure 3, B and C ). Immunofluorescent staining was then conducted to
check the pattern(s) of intracellular distribution and relative abun-
dance of LIF in the two cell lines with and without resveratrol treat-
ment (Figure 3A). Under normal culture condition, LIF protein was
evenly distributed in the cytoplasm of UW228-2 and -3 cells, which
became enriched in cytoplasm and accumulated in the form of mul-
tiple granules along the stretchy processes of resveratrol-treated cells.
To further confirm the distribution pattern of LIF, immunoelectron
microscopic examination was performed on UW228-3 cells, and LIF-
oriented Western blot analysis was on the concentrated condition me-
dium. As shown in Figure 3D, LIF proteins were labeled uniformly
in the cytoplasmic space of normally cultured/nontreated cells. The
LIF-labeling density became condensed in resveratrol-treated cells,
and some outward membrane-bounded particles on the surface of
cytoplasmic membrane were strongly positive in LIF. In parallel, West-
ern blot analysis performed on concentrated condition media dem-
onstrated that the level of LIF proteins was distinctly higher in the
medium of resveratrol-treated cells than that of their normally cultured
counterpart (Figure 3C ), suggesting the enhanced LIF secretion by
resveratrol. The LIF was undetectable in the concentrated medium
containing 10% FBS.
Effects of AG490 on Medulloblastoma Cells
To determine the correlation between the status of STAT3 activa-
tion and antimedulloblastoma effects of resveratrol, AG490, a selec-
tive inhibitor of STAT3 phosphorylation, was used to treat UW228-3
cells. Immunocytochemical staining demonstrated that STAT3 phos-
phorylation was inhibited in AG490-treated cells in terms of the
reduction of p-STAT3 nuclear labeling (Figure 4). Meanwhile, the pro-
liferation of UW228-3 cells was apparently suppressed by AG490 in a
time-related fashion. After AG490 treatment for 48 hours, the cells
became elongated with synaptophysin (Figure 4). The results of ICC
staining for c-Myc, Cox-2, cyclin D1, and survivin revealed that the
Figure 1. Evaluationof chemosensitivities ofUW228-2 andUW228-3
cells to resveratrol treatment by flow cytometry analysis (A) and
trypan blue discrimination of stained (unviable) and unstained (vi-
able) cells (B). 3R indicates resveratrol-treated UW228-3 cells; 2R,
resveratrol-treated UW228-2 cells; AD, cells died of apoptosis; G1,
cells at G1 phase.
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expression levels of those genes were decreased in AG490-treated
cells (Table 2). Similar with the findings from resveratrol-treated
cells, the levels of Bcl-2 and LIF expression were enhanced by
AG490 treatment (Table 2). However, apoptotic cells were hardly
observed throughout the course of AG490 treatment.
Discussion
Signal transducer and activator of transcription 3 signaling is the
important molecular machinery that regulates cell fate determination,
renewal, differentiation, and apoptosis of various cell types, especially
the ones at the embryonic developing stages [7,32,33]. When LIF-
and ciliary neurotrophic factor–mediated phosphorylation occurs to
STAT3 protein, the phosphorylated STAT3 shifts into nucleus and
promotes self-renewal of early neural progenitor cells (NPCs) [34]
or triggers GFAP expression in relatively late NPCs [35]. These phe-
nomena suggest that the role of STAT3 in neurodevelopment largely
depends on the stages where NPCs stay. Conversely, disordered
STAT3 signaling maymislead stepwise neurogenic processes and result
in primitive and unlimited proliferating statuses of NPCs [36–38].
Therefore, a link of STAT3 alteration to neuroectodermal tumor for-
mation has been proposed [15]. Resveratrol is an effective differentia-
tion and apoptosis inducer of medulloblastoma cells [6]. Although
resveratrol could induce certain molecular changes of medulloblas-
toma cells [9], its detailed molecular effects on those cells have not
been systemically clarified. Furthermore, despite the importance of
STAT3 in tumor formation and the potential values of resveratrol in
cancer prevention and treatment, their internal relation(s) in cancer
cells was rarely mentioned [17]. The current study thus aimed to shed
light on the above-mentioned issues.
Evaluation of the biologic effects of resveratrol on medulloblas-
toma cells revealed that this reagent arrested the cells at G1 phase
and induced differentiation and apoptosis of medulloblastoma cells.
UW228-3 cells were more sensitive to the treatment. The appearance
of synaptophysin but not GFAP expression in resveratrol-treated cells
suggests that UW228-2 and -3 cells remained at a self-renewal and
undifferentiated state, originally, and were promoted to the path of
neuronal differentiation by resveratrol. Because of the importance of
STAT3 signaling in the maintenance of medulloblastoma cells [15]
and its unfavorable effect(s) on neuronal differentiation [35], the
status of STAT3 expression and phosphorylation in the two medul-
loblastoma cell lines without and with resveratrol treatment was in-
vestigated by multiple approaches. Constitutive STAT3 expression
with nuclear translocation could be found in the two cell lines under
normal culture condition. On resveratrol treatment, STAT3 became
down-regulated in the transcriptional level accompanied by the rarity
of nuclear translocation. This finding demonstrated for the first time a
link of the antimedulloblastoma effects of resveratrol with the sup-
pressed STAT3 bioactivity. Signal transducer and activator of transcrip-
tion 3 signaling regulates the expressions of multiple cancer–associated
genes [8,13,14,39]. We therefore considered that its inactivation may
alter the expression patterns of its downstream genes, of which some
are crucial for cell growth and survival. Conversely, inhibition of
STAT3 signaling might release the undifferentiated medulloblastoma
cells for further differentiation, because diminished STAT3 may result
in down-regulation of inhibitory bHLH factors and directly induce
Figure 2. Evaluation of STAT3 phosphorylation and expression of survivin, cyclin D1, and Bcl-2 as well as Cox-2, c-Myc, and synapto-
physin in medulloblastoma cells by ICC and IF staining (A), RT-PCR (B), and Western blot analysis (C). NC indicates normally cultured/
nontreated cells; Res, 100-μM resveratrol-treated cells. β-Actin was used as a quantitative control in RT-PCR and Western blot analysis.
The negative data of GFAP examination were not shown.
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neuronal differentiation of NPCs [40]. The appearance of neuronlike
phenotype and synaptophysin expression in resveratrol-treated cell
populations supports this notion.
Activated STAT3 signaling is commonly found in human cancers
including medulloblastomas [15,16]. It plays oncogenic roles by pro-
moting the expression of a panel of cancer-associated genes such as cy-
clin D1, c-Myc, survivin, Cox-2, and Bcl-2 [8,13,14,41]. Given the
evidence of c-Myc down-regulation in resveratrol-treated UW228-2
and -3 cells [9], we speculated that the expression patterns of other
STAT3 target genes may also be altered in those cells on resveratrol
treatment. Just as what we had expected, in parallel with c-Myc
down-regulation, the levels of cyclin D1, Cox-2, and survivin were re-
duced in resveratrol-treated UW228-2 and, particularly, UW228-3
cells that were more sensitive to resveratrol. It is therefore reasonably
speculated that one of major antimedulloblastoma effects of resveratrol
would be the blockage of STAT3 signaling by directly suppressing
STAT3 transcription, which may abate STAT3 signaling and, conse-
quently, lead to the down-regulation of STAT3 target genes.
Bcl-2 is famous in preventing apoptotic cell death, and its expres-
sion is closely related with STAT3 activation [10]. Because resveratrol
committed UW228-2 and -3 cells to apoptosis [6], the influence of
resveratrol in Bcl-2 expression was speculated. Interestingly, Bcl-2
expression was enhanced in resveratrol-treated UW228-3 and, espe-
cially, UW228-2 cells. Although Bcl-2 down-regulation was usually
accompanied with apoptosis [42], the exceptional cases could also be
found in some cell types, e.g., enhanced Bcl-2 expression in the apop-
totic cardiac cells of chronic coronary heart disease [43,44], the he-
patocyte apoptosis of alcoholic steatohepatitis due to alcohol-related
stress [45], the treatment of multidrug-resistant cancer [46], and che-
moresistant acute lymphoblastic leukemia cells [47]. One possible ex-
planation to this phenomenon would be a feedback response to the
increased apoptotic pressure or a compensatory approach to the loss
of other cancer-associated gene expression, because in comparison
with UW228-3 cells, resveratrol-treated UW228-2 cells expressed
higher level of Bcl-2 and were subjected to lesser apoptosis in the
given times. In this context, the extent of Bcl-2 enhancement might
Figure 3. Analyses of LIF expression and intracellular distribution in UW228-3 cells without (NC) and with (Res) resveratrol treatment by
ICC and IF staining (A), immunoelectron microscopic examination (B), and RT-PCR and Western blot analysis (C). LIF secretion activity
was checked by Western blot analysis using concentrated condition media of UW228-3 cells cultured for 48 hours without and with
resveratrol treatment. The medium containing 10% FBS was used as background control (D). In (A), the arrows indicate the cells shown
in the inserts with high magnification. In (B), the magnification scales of electron microscopic illustrations are indicated as ×10K and
×20K (10,000 and 20,000 times); the black arrows indicate the vesicular structures and the red ones indicate the vesicles shown in
the inserts.
Neoplasia Vol. 10, No. 7, 2008 Resveratrol and STAT3 Signaling in Medulloblastoma Yu et al. 741
reflect the apoptotic susceptibility of medulloblastoma cells to resver-
atrol. In addition to STAT3, Bcl-2 can be regulated by other signaling
pathways such as the ones mediated by NF-κB or Wnt signaling
[17,48]. Therefore, more comprehensive investigation would be nec-
essary to get new insight into the overall alterations of signaling net-
work in resveratrol-treated medulloblastoma cells.
Leukemia inhibitory factor belongs to the member of IL-6 family,
which acts as a key upstream stimulator of the JAK/STATs signaling
[49]. For example, this protein could inhibit neuronal terminal dif-
ferentiation through activating STAT3 signaling [50]. In the absence
of IL-6 expression, LIF serves as a crucial autocrinal growth factor of
medulloblastoma cells because blockage of its expression or bioactiv-
ity commits medulloblastoma cells to apoptosis [19]. Because of the
close links of LIF with STAT3 signaling and medulloblastoma pro-
liferation, its status in resveratrol-treated cells was examined by mul-
tiple approaches. Similar with Bcl-2, LIF was up-regulated in both
UW228-2 and UW228-3 cells after resveratrol treatment. Moreover,
IF staining and immunoelectron microscopic examination showed
accumulated LIF-positive vesicular-like structures located beneath
plasma membrane and on the membrane outward the extracellular
space in resveratrol-treated cells, suggesting the increased activities
of LIF expression and secretion. The results of Western blot analysis
further confirmed this speculation by showing the higher LIF level in
the condition medium of resveratrol-treated cells than that of their
normally cultured counterpart and the undetectable LIF in the con-
centrated medium containing 10% FBS. The findings of elevated LIF
expression and secretion in resveratrol-treated cells reflect again the pres-
ence of feedback or compensatory response to the inactivation of STAT3
signaling by strengthening the activation stimuli in resveratrol-treated
cells. However, this response gives little help to the affected cells because
of the distinct reduction of STAT3 transcription. Apparently, the inhi-
bition of STAT3 expression and signaling would be a fundamental event
in resveratrol-treated medulloblastoma cells, although the detail molec-
ular mechanism of resveratrol-modulated STAT3 transcription awaits
further investigation.
AG490, a JAK-specific inhibitor, can significantly suppress STAT3
signaling by inhibiting the phosphorylation of Tyr705 of STAT3 [38].
We therefore used it to block the JAK/STATsignaling in medulloblas-
toma cells. Together with the inhibition of STAT3 phosphorylation
and c-Myc, survivin, and cyclin D1 expressions, cell growth was sup-
pressed efficiently, and the cell shape became elongated along with
synaptophysin expression, a similar phenotype as we have observed in
resveratrol-treated cells. These findings further support the roles of
STAT3 signaling in promoting proliferation and maintaining the un-
differentiated status of medulloblastoma cells. However, unlike resver-
atrol, AG490 did not lead to an apoptotic death of medulloblastoma
cells. This phenomenon may have two implications: 1) other compen-
satory mechanism(s) may remain intact to sustain the survival of af-
fected cells when only STAT3 signaling is inhibited by AG490; and
2) in addition to STAT3, other molecular elements in resveratrol-
treated medulloblastoma cells may also be altered, resulting in more
crucial events than that evoked by AG490.
Figure 4. Morphologic changes, synaptophysin expression and the state of STAT3 phosphorylation of UW228-3 cells without (NC) and
with AG490 treatment. The expression patterns of STAT3 downstream genes in those cells are summarized in Table 2.
Table 2. STAT3 Phosphorylation and Medulloblastoma-Associated Gene Expression in UW228-3
Cells Under Three Culture Conditions.
Normal Culture Resveratrol AG490
p-STAT3 ++ ± −
c-Myc ++ + +
cyclin D1 + ± ±
survivin ++ + +
Cox-2 ++ − ±
LIF + ++ ++
Bcl-2 + ++ +
synaptophysin − + +
742 Resveratrol and STAT3 Signaling in Medulloblastoma Yu et al. Neoplasia Vol. 10, No. 7, 2008
In summary, we found for the first time that resveratrol inhibited
STAT3 signaling, by directly suppressing STAT3 transcription, and
induced neuronal differentiation and apoptosis of medulloblastoma
cells. Although some STAT3 downstream genes such as survivin, cy-
clin D1, Cox-2, and c-Myc were down-regulated, Bcl-2 and LIF were
overexpressed in resveratrol-treated cells, indicating the presence of
feedback and/or compensatory response(s) to the apoptosis pressure
and to the disordered STAT3 signaling. The limitation of AG490 in
apoptosis induction suggests that additional survival machineries in
medulloblastoma cells may also be altered by resveratrol. Our study
thus provides strong evidence for the fundamental roles of STAT3 sig-
naling in maintaining the undifferentiation, proliferation, and survival
of medulloblastoma cells and the suppressive effects of resveratrol on
the expressions of STAT3 and its so-called target genes. Further anal-
ysis will focus on the molecular mechanism of resveratrol-caused
STAT3 gene silencing.
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